Neoplasm Malignant Clinical Trial
Official title:
A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer
Primary Objectives:
To determine the recommended Phase 2 dose of SAR405838 / pimasertib combination therapy in
patients with solid tumors.
To assess the anti-tumor activities of SAR405838 / pimasertib in patients with solid tumors.
Secondary Objectives:
To characterize the pharmacokinetic profile of SAR405838 and pimasertib.
To evaluate the pharmacodynamic effect of the SAR405838 and pimasertib.
To characterize genetic status in tumor tissue and circulating tumor DNA.
The duration of the study for an individual patient will include a period to assess eligibility of up to 4 weeks, a treatment period of at least 6 weeks of study treatment, and an end-of-study visit at least 30 days (or until the patient receives another anti-cancer therapy, whichever is shorter) following the last administration of study drug. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01156870 -
First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor
|
Phase 1 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01930552 -
A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01657214 -
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
|
Phase 1 | |
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Completed |
NCT02575781 -
A Study of SAR428926 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01943838 -
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT03324113 -
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06238687 -
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02435121 -
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
|
Phase 2 | |
| Completed |
NCT01455532 -
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04067388 -
iKnife REIMS Project
|
||
| Completed |
NCT01836705 -
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01140607 -
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
|
Phase 1 | |
| Recruiting |
NCT04495790 -
AIMS Cancer Outcomes Study
|
||
| Recruiting |
NCT05714553 -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04733469 -
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
|
N/A | |
| Active, not recruiting |
NCT03845166 -
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01596270 -
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
|
Phase 1 |